

JOURNAL EDITORIAL BOARD'S REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 88728

Title: Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Journal Editor-in-Chief/Associate Editor/Editorial Board Member: Joseph M Pappachan

Country/Territory: United Kingdom

Editorial Director: Jia-Ru Fan

Date accepted review: 2024-02-05 20:23

Date reviewed: 2024-02-05 20:44

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair		<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Major revision

JOURNAL EDITORIAL BOARD COMMENTS TO AUTHORS

- There are several language errors throughout the paper which need rectification (e.g., "high glucose induced...." should have been hyperglycaemia-induced; "primary mouse cardiomyocyte were treated...." syntax error; the last sentence in the results of abstract makes no sense.) with a language expert/ editing service. - The first sentence in the abstract results section is quite unclear with the poor syntax and sentence structure. What is meant by the term heart weight/ tibia length? - Introduction: sentence 3 giving figures about diabetes prevalence is from old estimates. Please quote and and cite the 2022 figures. - Methods: The number of mouse model used in the experiments (total 6 including controls I assume) seems small which makes reproducibility of the research questionable. This appears a major limitation of the study. - Discussion section makes comments about evogliptin and alogliptin roles in DCM which make not much sense. If authors wanted to discuss the potential



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

effects of various DPP-IV agents on DCM, these should have been in the introduction/ background section. - There should be a short discussion on what this study adds to our knowledge and the main limitations of the work in before conclusion section.